| 1 |
12/01/2007 |
18025241 |
Cross-Reactive CD4+ T Cells against One Immunodominant Tumor-Derived Epitope in Melanoma Patients. |
|
| |
TCRs exhibit a high degree of specificity but may also recognize multiple and distinct peptide-MHC complexes, illustrating the so-called cross-reactivity of TCR-peptide-MHC recognition. In this study,...
|
| 2 |
12/01/2007 |
17929270 |
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. |
|
| |
BACKGROUND: Active immunotherapies are one approach being developed as novel treatments for prostate cancer. Critical to the success of these therapies is the identification of appropriate target anti...
|
| 3 |
12/01/2007 |
17522859 |
Specific CD8(+ )T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. |
|
| |
The MAGE-A3 protein, one of the promising tumor antigens for immunotherapy, is highly expressed in human hepatocellular carcinoma (HCC). In this study, we estimated the specific CD8(+) T cell immune r...
|
| 4 |
11/20/2007 |
18045611 |
Identification of prostate cancer antigens by automated high-throughput filter immunoscreening. |
|
| |
There is a need for earlier and more accurate cancer diagnostics as well as new targets for cancer immunotherapy. To this end, it is important to identify sets of tumour antigens specific for differen...
|
| 5 |
11/07/2007 |
17991294 |
Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells. |
|
| |
The cancer-testis antigen NY-ESO-1 has been implicated as one of the most attractive candidates for a cancer vaccine. However, a protein vaccine generally meets inefficient antigen presentation to CD8...
|
| 6 |
11/06/2007 |
17986662 |
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. |
|
| |
Salmonella typhimurium engineered to deliver cancer/testis antigen NY-ESO-1 through type III secretion (S. typhimurium-NY-ESO-1) was shown to be an efficient cancer vaccine construct in mice and to st...
|
| 7 |
11/01/2007 |
17947658 |
High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines. |
|
| |
We examined the activity of human T cells engineered to express variants of a single TCR (1G4) specific for the cancer/testis Ag NY-ESO-1, generated by bacteriophage display with a wide range of affin...
|
| 8 |
11/01/2007 |
17640060 |
Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. |
|
| |
A major objective of peptide vaccination is the induction of tumor-reactive CD8+ T-cells. We have shown that HLA-A2 positive cancer patients frequently develop an antigen-specific CD8+ T-cell response...
|
| 9 |
10/24/2007 |
17959670 |
Immunisation with a lentivector that targets tumour antigen expression to dendritic cells induces potent CD8+ and CD4 + T cell responses. |
|
| |
Lentivectors stimulate potent immune responses to antigen transgenes and are being developed as novel genetic vaccines. To improve safety while retaining efficacy, we constructed a lentivector in whic...
|
| 10 |
10/18/2007 |
17950595 |
Cancer testis antigen expression in primary and recurrent vulvar cancer: Association with prognostic factors. |
|
| |
Cancer testis tumour associated antigens (C/T-TAAs) were investigated in several gynaecologic and non-gynaecologic neoplasms as possible prognostic markers and targets for immunotherapy. The objective...
|
| 11 |
10/11/2007 |
17932110 |
Autoantibodies in Lung Cancer - possibilities for early detection and subsequent cure. |
|
| |
Background Individuals with lung cancer usually present at a late stage in the course of their disease when their chances of long term survival are low. At present there is little to offer for early d...
|
| 12 |
07/31/2007 |
17652518 |
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. |
|
| |
NY-ESO-1 is a "cancer-testis" antigen expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor antigens defined to date. The NY-ESO-1 peptide epitope, ESO(157-170), is reco...
|
| 13 |
07/24/2007 |
17650306 |
Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. |
|
| |
ABSTRACT: INTRODUCTION: Cancer-testis antigens (CTAGs) are expressed solely in germ cells and in malignant tissues. They are targets of immune responses mediated by cytotoxic T cells in some cancers, ...
|
| 14 |
07/18/2007 |
17320278 |
Potential target antigens for immunotherapy in human pancreatic cancer. |
|
| |
BACKGROUND: To be effective and selective, immunotherapy ideally targets specifically tumor cells and spares normal tissues. Identification of tumor specific antigens is a prerequisite to establish an...
|
| 15 |
07/01/2007 |
17488334 |
Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population. |
|
| |
NY-ESO-1 is a cancer-testis antigen that elicits strong cellular and humoral immune responses against NY-ESO-1-expressing tumors. Although CD4(+) T cells play a critical role in inducing antitumor imm...
|
| 16 |
07/01/2007 |
17096152 |
Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma. |
|
| |
Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy, and despite advances in treatments, the 5-year survival has remained at less than 50%. One treatment strategy is to focus on ...
|
| 17 |
06/28/2007 |
17260018 |
Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. |
|
| |
Previously, we reported that the paralogous zinc-finger proteins--CTCF and brother of the regulator of imprinted sites (BORIS), directly contribute to transcriptional regulation of NY-ESO-1 in lung ca...
|
| 18 |
06/20/2007 |
17637219 |
Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma. |
|
| |
BACKGROUND: Cancer-testis antigen (CTA) is a family of the most noticeable tumor antigens which could be potential tumor markers for cancer diagnosis. In this research we aimed to investigate the expr...
|
| 19 |
06/01/2007 |
17294444 |
NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. |
|
| |
NY-ESO-1 is a cancer testis antigen expressed in various malignancies and testicular germ cells. Because of its capacity to induce specific humoral and cellular immunity in patients with NY-ESO-1-posi...
|
| 20 |
06/01/2007 |
16960690 |
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. |
|
| |
Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for the development of T cell vaccines. Whereas CT antigens are frequently expressed in melanoma, their ...
|
